Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Target not currently curated in GtoImmuPdb
Target id: 1792
Nomenclature: activin A receptor type 2B
Abbreviated Name: ActR2B
| Quaternary Structure: Complexes |
| Bone morphogenetic protein receptors |
| Growth/differentiation factor receptors |
| Activin receptors |
Gene and Protein Information ![]() |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 512 | 3p22.2 | ACVR2B | activin A receptor type 2B | |
| Mouse | 1 | 536 | 9 F3 | Acvr2b | activin receptor IIB | |
| Rat | 1 | 513 | 8q32 | Acvr2b | activin A receptor type 2B | |
Previous and Unofficial Names ![]() |
| activin receptor IIB | Activine receptor 2b (transmembrane serine kinase) | Acvr2 | activin receptor 2B | ActRIIB | activin A receptor type IIB |
Database Links ![]() |
|
| Alphafold | Q13705 (Hs), P27040 (Mm), P38445 (Rn) |
| BRENDA | 2.7.11.30 |
| ChEMBL Target | CHEMBL5466 (Hs) |
| Ensembl Gene | ENSG00000114739 (Hs), ENSMUSG00000061393 (Mm), ENSRNOG00000014477 (Rn) |
| Entrez Gene | 93 (Hs), 11481 (Mm), 25366 (Rn) |
| Human Protein Atlas | ENSG00000114739 (Hs) |
| KEGG Enzyme | 2.7.11.30 |
| KEGG Gene | hsa:93 (Hs), mmu:11481 (Mm), rno:25366 (Rn) |
| OMIM | 602730 (Hs) |
| Orphanet | ORPHA159918 (Hs) |
| Pharos | Q13705 (Hs) |
| RefSeq Nucleotide | NM_001106 (Hs), NM_007397 (Mm), NM_031554 (Rn) |
| RefSeq Protein | NP_001097 (Hs), NP_031423 (Mm), NP_113742 (Rn) |
| UniProtKB | Q13705 (Hs), P27040 (Mm), P38445 (Rn) |
| Wikipedia | ACVR2B (Hs) |
Selected 3D Structures ![]() |
|||||||||||
|
|
||||||||||
Enzyme Reaction ![]() |
||||
|
||||
Natural/Endogenous Ligands ![]() |
| myostatin {Sp: Human} |
Download all structure-activity data for this target as a CSV file
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
DiscoveRx KINOMEscan® screen ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 2,4 |
![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Target used in screen: ACVR2B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Displaying the top 10 most potent ligands View all ligands in screen » | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||
|
||||||||||||||
1. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013) Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013.
2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
3. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD. (2007) A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol, 7: 6. [PMID:17295905]
4. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]